Redeye updates our outlook ahead of the European and the US launch of XVIVO’s Heart cold continuous oxygenated perfusion solution. The regional support in Australia and New Zealand together with clinical evidence suggest that this is a major opportunity. We expect that XVIVO’s heart solution alone can match XVIVO’s annual 2023E sales by 2027E and contribute to one third of our sales CAGR by 20231E. We increase our base case to SEK 450 (415) with a Bull of SEK 950 (800) and a Bear of SEK 105.